Kalamazoo, Mich.-based Ablative Solutions Inc. is looking to make a mark in the hypertension space. To that end, it has reported the first close of its $77 million series D funding round to back the completion of clinical trials for U.S. and European regulatory submissions for its renal denervation technology.

Berkeley, Calif.-based Iota Biosciences Inc. has raised a $15 million series A round to get into a first-in-human pilot study for its bioelectronics implants. The field of bioelectronics aims to develop super tiny implants that effectively shift fundamental disease processes via neuromodulation, thereby potentially replacing pharmaceutical treatments with a safer, more effective, nonsystemic alternative.